Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.
Vous n'êtes pas connecté
MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.
Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer,...
FORMER journalist and Independent Senator Sunity Maharaj says constitutional reform is the beginning of a means to begin to anchor a culture of...
European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline...
The New Patriotic Party’s running mate Dr Matthew Opoku Prempeh has pointed out what he calls the failures of the opposition National Democratic...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it...
By Niranjan Chandrashekhar Oak China is expanding and modernising its nuclear arsenal at an unprecedented speed. China’s development of newer...
Commissioner of Elections Susan Beals on Wednesday expressed concerns with the operational performance of the U.S. Postal Service ahead of the 2024...